BioSpace News Archive

The early-stage oncology startup filed for an initial public offering on Wednesday, seeking funds to help develop its novel cancer therapies targeting extrachromosomal DNA.

President Joe Biden has proposed expansions to the Inflation Reduction Act, including an increase in the annual number of prescription drugs that would be subject to price negotiations to 50, up from 20.

The FDA’s busy week ahead involves three decision dates for potential industry firsts and a highly anticipated advisory committee meeting for two CAR-T therapies.

The antibody-drug conjugate beat the standard of care in second-line multiple myeloma, the company reported on Thursday, as it seeks to get the cancer drug back on the U.S. market.

The Anglo-Swedish drugmaker is making the investment to bolster its vaccine manufacturing and research and development capabilities in the U.K.

Novo Nordisk’s early-stage amylin and GLP-1 co-agonist elicited a 13.1% reduction in body weight, with an overall favorable safety profile, the Danish drugmaker reported Thursday at an investor event.

Gilead Sciences is partnering with Dutch biotech Merus to find novel dual tumor-associated antigens that target tri-specific antibodies.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization, announced the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029.

BioArctic AB’s partner Eisai published a presentation including a simulation of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease.

Zylox-Tonbridge, a leading medical device company in the peripheral and neurovascular interventional market in China, announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease.